ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2016
Advancing surveillance of antimicrobial resistance: Summary of the 2015 CIDSC Report.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Estimating the undetected burden and the likelihood of strain persistence of drug-resistant Neisseria gonorrhoeae.American journal of epidemiology · 2025Article
- Biological activities of optimized biosynthesized selenium nanoparticles using Proteus mirabilis PQ350419 alone or combined with chitosan and ampicillin against common multidrug-resistant bacteria.Microbial cell factories · 2025Article
- Article
- Mandatory surveillance of bacteremia conducted by automated monitoring.Frontiers in public health · 2024Article
- Prevalence of antimicrobial-resistant organisms in smaller Canadian hospitals: Community, Rural, and Northern Acute Care Point Prevalence (CNAPP-19) Survey, 2019.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Antimalarial Drug Resistance and Implications for the WHO Global Technical Strategy.Current epidemiology reports · 2021Review
- Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries.Journal of medical Internet research · 2020Article
- Epidemiology ofCanada communicable disease report = Releve des maladies transmissibles au Canada · 2019Article
- Emerging risk of untreatable gonorrhea and what to do about it.Canadian family physician Medecin de famille canadien · 2017Article
- How is an international public health threat advanced in Canada? The case of antimicrobial resistance.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobials are essential for the treatment and control of infectious diseases and therefore, the development and spread of antimicrobial resistance (AMR) is a global health concern. It is recognized that robust AMR surveillance is necessary; however, current gaps in national surveillance programs need to be addressed to enable better evidence-informed program and policy decisions.
objectiveTo describe how an AMR Surveillance Task Group prioritized national AMR surveillance data requirements for high priority AMR organisms for human health in Canada and made recommendations on addressing the current data gaps.
methodsThe 2015 AMR Surveillance Task Group examined the data requirements for previously identified first priority organisms and assessed whether the current system met, partially met or did not meet these requirements. Information was summarized into synopsis tables and a ranking process was used to prioritize the data requirements and develop specific recommendations to address the gaps.
resultsFirst priority organisms identified for AMR surveillance are:
conclusionWhile current national surveillance programs either capture or partially capture many of the identified data requirements for first priority organisms, several gaps still remain, especially in community settings. A national review of the recommendations of the Task Group is underway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.